ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation
September 29 2022 - 7:00AM
Business Wire
ImprimisRx, America’s #1 Ophthalmic Pharmacy™, today announced
the availability of Fortisite™, which includes a patent-pending
compounded combination of Tobramycin 1.5% and Vancomycin 5%.
Compounded topical antibiotic formulations may be appropriate to
prescribe for patients with clinical needs that are unmet by
FDA-approved drug products. Fortisite, which includes a compounded
combination antibiotic formulation (Tobramycin 1.5% and Vancomycin
5%) in solution, is tested for both potency and sterility before it
is dispensed, and uniquely, is stable at refrigerated temperatures
(5°C) for up to 180 days.
Fortisite formulations are currently available for individual
patients through the ImprimisRx 503A national mail order pharmacy.
Once available through the ImprimisRx FDA-registered and
FDA-inspected 503B outsourcing facility, which is expected in the
first half of 2023, physicians will be able, for the first time, to
stock a fortified or high-concentration compounded antibiotic in
their offices for the immediate treatment of patients-in-need. In
addition, consistent with its commitment to patient access,
ImprimisRx will provide a robust Patient Access Program and a 100%
replacement guarantee for any expired 503B Fortisite product,
ensuring all U.S. eyecare professionals can continuously stock
Fortisite formulations in their offices without the additional
expense associated with expired product replacement.
Eyecare professionals interested in learning more about
Fortisite are invited to visit the ImprimisRx Boutique (Booth
#4416) at the American Academy of Ophthalmology (AAO) meeting,
which will take place Friday, September 30, 2022, through Monday,
October 3, 2022, at McCormick Place in Chicago, Illinois.
To order Fortisite online, go to ImprimisRx.com/fortified, or
call ImprimisRx Customer Care at 844-446-6979. Same-day shipping is
currently available Monday through Friday for patients if a
complete prescription is received by 12pm PT (3pm ET).
PLEASE REVIEW THE FORTISITE PACKAGE INSERT
BEFORE PRESCRIBING.
About ImprimisRx
ImprimisRx is the nation’s leading ophthalmology-focused
compounded pharmaceuticals brand, serving thousands of
ophthalmologists and optometrists in all 50 states, with over 25
proprietary compounded ophthalmic formulations. For more
information about ImprimisRx, including product ordering
instructions, please visit imprimisrx.com. ImprimisRx is a wholly
owned subsidiary of Harrow (NASDAQ: HROW).
Forward-Looking Statements of Harrow
This press release contains “forward-looking statements” within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties which may
cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include the continued impact of the COVID-19 pandemic and
any future health epidemics on our financial condition, liquidity
and results of operations; our ability to make commercially
available our FDA-approved products and compounded formulations and
technologies in a timely manner or at all; market acceptance of the
Company’s products and challenges related to the marketing of the
Company’s products; risks related to our pharmacy operations; our
ability to enter into other strategic alliances, including
arrangements with pharmacies, physicians and healthcare
organizations for the development and distribution of our products;
our ability to obtain intellectual property protection for our
assets; our ability to accurately estimate our expenses and cash
burn, and raise additional funds when necessary; risks related to
research and development activities; the projected size of the
potential market for our technologies and products; unexpected new
data, safety and technical issues; regulatory and market
developments impacting compounding pharmacies, outsourcing
facilities and the pharmaceutical industry; competition; and market
conditions. These and additional risks and uncertainties are more
fully described in Harrow’s filings with the Securities and
Exchange Commission, including its Annual Report on Form 10-K and
its Quarterly Reports on Form 10-Q. Such documents may be read free
of charge on the SEC's web site at www.sec.gov. Undue reliance
should not be placed on forward-looking statements, which speak
only as of the date they are made. Except as required by law,
Harrow undertakes no obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
* ImprimisRx specializes in customizing medications to meet
unique patient and practitioner needs. No compounded medication is
reviewed by the FDA for safety or efficacy. ImprimisRx does not
compound copies of commercially available products.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220929005297/en/
Investors Jamie Webb
Director of Communications and Investor Relations
jwebb@harrowinc.com 615-733-4737
Media Deb Holliday Holliday
Communications, Inc. deb@hollidaycommunications.net
412-877-4519
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Aug 2024 to Sep 2024
Harrow (NASDAQ:HROW)
Historical Stock Chart
From Sep 2023 to Sep 2024